NCT05614024 Neurofeedback During Eating for Bulimia Nervosa
| NCT ID | NCT05614024 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Bulimia Nervosa |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-05-13 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-05-13 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.
Eligibility Criteria
Inclusion criteria: * Female * Aged 18 to 45 years * Meet diagnostic criteria for bulimia nervosa * Current body mass index greater than or equal to 18.5kg/m2 but under 30kg/m2 * English-speaking Exclusion criteria: * Ongoing medical treatment, major medical condition, or psychiatric disorder that may interfere with study variables or participation * Current psychotherapy focused primarily on eating disorder symptoms * Pregnancy or planned pregnancy, or lactation during the study period * Allergy to ingredients in the standardized meal or in the shake
Contact & Investigator
Laura A Berner, Ph.D.
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT05614024 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Bulimia Nervosa. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05614024 currently recruiting?
Yes, NCT05614024 is actively recruiting participants. Contact the research team at sila.sozeri@mssm.edu for enrollment information.
Where is the NCT05614024 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05614024 clinical trial?
NCT05614024 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Laura A Berner, Ph.D. at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 30 participants.